# Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2017

- Company: [Amphastar Pharmaceuticals, Inc.](/companies/amph.md) (CIK 1297184)
- Form: 10-Q
- Filed: 2017-08-09
- Accepted by EDGAR: Aug 9, 2017, 17:21 ET
- Period: 2017-06-30
- Accession: 0001297184-17-000028
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1297184/000129718417000028/amph-20170630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1297184/000129718417000028/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2017-01-01 to 2017-06-30 | $121.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $38.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2017-01-01 to 2017-06-30 | $72.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $26.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $49.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $10.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $22.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | $2.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | $3.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $237.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $428.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $2.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | $2.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 47,866,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 47,962,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $13.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2017-01-01 to 2017-06-30 | $17.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-06-30 | $82.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $193.6m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $444.0m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $63.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $110.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-06-30 | $333.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 31,169 characters.

*The following is a discussion and analysis of the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the “Condensed Consolidated Financial Statements” and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2016, particularly in Item 1A. “Risk Factors”.*

### Overview

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation and intranasal products. Additionally, we sell insulin API products. We currently manufacture and sell 19 products. Additionally, we are developing a portfolio of 16 generic ANDAs, three generic biosimilar product candidates and six proprietary injectable and inhalation product candidates.

One of our largest products by net revenues is enoxaparin sodium injection, the generic equivalent of Sanofi S.A.’s Lovenox®. Enoxaparin is a difficult to manufacture injectable form of low molecular weight heparin that is used as an anticoagulant and has multiple indications, including the prevention and treatment of deep vein thrombosis.

We have agreements with established group purchasing organizations and wholesaler networks to distribute enoxaparin, which is marketed under our own label for the hospital and clinic market. For the U.S. retail market, we had a distribution agreement with Actavis Inc., or Actavis, to distribute enoxaparin, which was marketed under Actavis’ label. On June 30, 2016, we amended the distribution agreement with Actavis, to among other things, amend the termination date of such agreement. In December 2016, our distribution agreement was terminated pursuant to such amendment. Since December 2016, we have been distributing enoxaparin directly in the U.S. retail marketing under our own label.

Our pipeline of over 20 generic and proprietary product candidates is in various stages of development and targets a variety of indications. With respect to these product candidates, we have six ANDAs, and two NDAs on file with the FDA.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our core injectable and inhalation product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities including the ability to manufacture raw materials, APIs and other components for our products.

Included in these acquisitions are marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities, from UCB Pharma GmbH. We plan to transfer the manufacturing of these products to our facilities in California, which will require approvals from the UK Medicines and Healthcare products Regulatory Agency before the product candidates can be re-launched by us.

### Business Segments

Our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) API products. The finished pharmaceutical products segment currently manufactures, markets and distributes enoxaparin, Cortrosyn®, Amphadase®, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment currently manufactures and distributes RHI API, and porcine insulin API. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.

For more information regarding our segments, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Segment Reporting”.

### Results of Operations

### Three Months Ended June 30, 2017 Compared to Three Months Ended June 30, 2016

### Net revenues

*(in thousands)*

| Net revenues | Three Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Finished pharmaceutical products | $63,765 | $63,756 | $9 | 0% |
| API | 1,422 | 4,277 | (2,855) | (67)% |
| Total net revenues | $65,187 | $68,033 | $(2,846) | (4)% |
| Cost of revenues |  |  |  |  |
| Finished pharmaceutical products | $34,899 | $33,159 | $1,740 | 5% |
| API | 3,541 | 3,160 | 381 | 12% |
| Total cost of revenues | $38,440 | $36,319 | $2,121 | 6% |
| Gross profit | $26,747 | $31,714 | $(4,967) | (16)% |
| as % of net revenues | 41% | 47% |  |  |

The increase in net revenues of the finished pharmaceutical products for the three months ended June 30, 2017, was due to the following changes:

*(in thousands)*

| Finished pharmaceutical products net revenues | Three Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Enoxaparin | $8,288 | $17,328 | $(9,040) | (52)% |
| Naloxone | 10,261 | 15,561 | (5,300) | (34)% |
| Epinephrine | 10,648 | 5,226 | 5,422 | 104% |
| Lidocaine | 9,334 | 8,191 | 1,143 | 14% |
| Phytonadione | 10,003 | 8,761 | 1,242 | 14% |
| Other finished pharmaceutical products | 15,231 | 8,689 | 6,542 | 75% |
| Total finished pharmaceutical products net revenues | $63,765 | $63,756 | $9 | 0% |

The decrease in sales of enoxaparin was primarily driven by lower unit volumes, which resulted in a decrease of approximately $7.1 million, as well as lower average selling prices, which resulted in a decrease of approximately $1.9 million. We expect that the average selling price and unit volumes of enoxaparin will continue to fluctuate in the near term as a result of competition.

Lower unit volumes of naloxone led to a decrease in sales of approximately $4.8 million, while lower average selling price caused a decrease in sales of approximately $0.5 million. We anticipate that sales of this product may fluctuate due to increased competition driven by future competitor launches.

The increase in sales of lidocaine and phytonadione sales were primarily the result of higher unit volumes. An increase in average selling prices of epinephrine caused an increase of approximately $3.0 million in net revenues, while higher unit volumes led to an increase in sales of approximately $2.4 million. The FDA requested that we discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which has been marketed under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. We discontinued selling this product in the second quarter of 2017. For the three months ended June 30, 2017, we recognized $9.9 million in net revenues for the sale of this product.

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. However, we had a significant backlog as of March 31, 2017, primarily due to decreased production at our IMS facility resulting from a partial plant shutdown. During the second quarter of 2017, we fulfilled such backlog. As a result, our other finished pharmaceutical products experienced a volume increase in the quarter. Our backlog is generally not a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

Sales of RHI API decreased because there were no sales to MannKind. We anticipate that sales of our API business will continue to fluctuate and will likely decrease due to the inherent uncertainties related to sales of RHI API to MannKind. In addition, most of our API sales are denominated in Euros, and the fluctuation in the value of the Euro versus the dollar has had, and will continue to have, an impact on API sales revenues in the near term.

### Cost of revenues

The increase in cost of revenue was due to an increase in the unabsorbed manufacturing expense and a charge of $4.7 million to adjust certain inventory items to their net realizable value, including $2.9 million for enoxaparin inventory items due to a decrease in the forecasted average selling price.

Volatility in average selling prices and unit volume of enoxaparin and the discontinuation of our epinephrine injection, USP vial product will put downward pressure on our gross margins. However, we believe that this trend will be partially offset by increases in prices and unit volumes of several other finished pharmaceutical products. As a result, gross margin is expected to be variable depending on revenue mix.

### Selling, distribution and marketing, and general and administrative

*(in thousands)*

|  | Three Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling, distribution, and marketing | $1,596 | $1,332 | $264 | 20% |
| General and administrative | 12,234 | 9,458 | 2,776 | 29% |

The increase in general and administrative expenses was primarily due to an increase in legal fees in preparation for our July 2017 patent trial (see Note 17 to the condensed consolidated financial statements for more information).

We expect that general and administrative expenses will increase on an annual basis due to increased costs associated with ongoing compliance with public company reporting obligations as well as legal fees associated with our enoxaparin litigation.

### Research and development

*(in thousands)*

|  | Three Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries and personnel-related expenses | $3,490 | $3,368 | $122 | 4% |
| Clinical trials | 1,216 | 153 | 1,063 | 695% |
| FDA fees | 85 | 2,388 | (2,303) | (96)% |
| Testing, operating and lab supplies | 4,003 | 2,543 | 1,460 | 57% |
| Depreciation | 1,111 | 1,183 | (72) | (6)% |
| Other expenses | 827 | 959 | (132) | (14)% |
| Total research and development expenses | $10,732 | $10,594 | $138 | 1% |

- 38-

Research and development costs consist primarily of costs associated with the research and development of our product candidates, such as salaries and other personnel related expenses for employees involved with research and development activities, manufacturing pre-launch inventory, clinical trials, FDA fees, testing, operating and lab supplies, depreciation and other related expenses. We expense research and development costs as incurred.

Testing, operating and lab supplies increased due to expenditures on materials for our pipeline products. Clinical trials expense increased due to external studies related to our generic product pipeline. This increase was partially offset by a decrease in FDA fees pertaining to the NDA filing of our intranasal naloxone product candidate that was submitted in the second quarter of 2016.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. These costs will fluctuate significantly from quarter to quarter based on the timing of various clinical trials, the pre-launch costs associated with new products, and FDA filing fees. As we undertake new and challenging research and development projects, we anticipate that the associated annual costs will increase significantly over the next several quarters and years.

### Provision for income tax expense

*(in thousands)*

|  | Three Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Income tax expense | $1,201 | $2,857 | $(1,656) | (58)% |
| Effective tax rate | 38% | 29% |  |  |

The difference in income tax expense was primarily due to the change in pre-tax income positions.

### Six Months Ended June 30, 2017 Compared to Six Months Ended June 30, 2016

### Net revenues

*(in thousands)*

| Net revenues | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Finished pharmaceutical products | $119,699 | $122,310 | $(2,611) | (2)% |
| API | 2,158 | 5,089 | (2,931) | (58)% |
| as % of net revenues | $121,857 | $127,399 | $(5,542) | (4)% |
| Cost of revenues |  |  |  |  |
| Finished pharmaceutical products | $66,523 | $65,888 | $635 | 1% |
| API | 5,759 | 4,895 | 864 | 18% |
| Total cost of revenues | $72,282 | $70,783 | $1,499 | 2% |
| Gross profit | $49,575 | $56,616 | $(7,041) | (12)% |
| as % of net revenues | 41% | 44% |  |  |

- 39-

The decrease in net revenues of the finished pharmaceutical products for the six months ended June 30, 2017, was due to the following changes:

*(in thousands)*

| Finished pharmaceutical products net revenues | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Enoxaparin | $18,698 | $35,686 | $(16,988) | (48)% |
| Naloxone | 21,200 | 25,815 | (4,615) | (18)% |
| Lidocaine | 17,622 | 18,099 | (477) | (3)% |
| Phytonadione | 17,890 | 14,887 | 3,003 | 20% |
| Epinephrine | 20,222 | 9,618 | 10,604 | 110% |
| Other finished pharmaceutical products | 24,067 | 18,205 | 5,862 | 32% |
| Total finished pharmaceutical products net revenues | $119,699 | $122,310 | $(2,611) | (2)% |

The decrease in sales of enoxaparin was primarily driven by lower unit volumes, which resulted in a decrease of approximately $12.8 million, as well as lower average selling prices, which resulted in a decrease of approximately $4.2 million. We expect that the average selling price and unit volumes of enoxaparin will continue to fluctuate in the near term as a result of competition.

Lower unit volumes of naloxone led to a decrease in sales of approximately $4.3 million, while lower average selling price caused a decrease in sales of approximately $0.3 million. We anticipate that sales of this product may fluctuate due to increased competition driven by future competitor launches.

The increase in phytonadione sales was primarily the result of higher unit volumes. An increase in average selling prices of epinephrine caused an increase of approximately $5.4 million in net revenues, while higher unit volumes led to an increase in sales of approximately $5.2 million. The FDA requested that we discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which has been marketed under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. We discontinued selling this product in the second quarter of 2017. For the six months ended June 30, 2017, we recognized $17.9 million in net revenues for the sale of this product.

Sales of RHI API decreased because there were no sales to MannKind. We anticipate that sales of API will continue to fluctuate and will likely decrease due to the inherent uncertainties related to sales of RHI API to MannKind. In addition, most of our API sales are denominated in Euros, and the fluctuation in the value of the Euro versus the dollar has had, and will continue to have, an impact on API sales revenues in the near term.

### Cost of revenues

The increase in cost of revenues was due to an increase in the unabsorbed manufacturing expense and a charge of $5.1 million to adjust certain inventory items to their net realizable value, including $2.9 million for enoxaparin inventory items due to a decrease in the forecasted average selling price.

Volatility in average selling prices and unit volume of enoxaparin and the discontinuance of our epinephrine injection, USP vial product will put downward pressure on our gross margins. However, we believe that this trend will be partially offset by increases in prices and unit volumes of several other finished pharmaceutical products. As a result, gross margin is expected to be variable depending on revenue mix.

### Selling, distribution and marketing, and general and administrative

*(in thousands)*

|  | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling, distribution, and marketing | $3,075 | $2,684 | $391 | 15% |
| General and administrative | 23,572 | 20,328 | 3,244 | 16% |

The increase in general and administrative expenses was primarily due to an increase in legal fees in preparation for our July 2017 patent trial (see Note 17 to the condensed consolidated financial statements for more information).

### Research and development

*(in thousands)*

|  | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries and personnel-related expenses | $7,470 | $6,955 | $515 | 7% |
| Pre-launch inventory | 711 | — | 711 | N/A |
| Clinical trials | 2,051 | 997 | 1,054 | 106% |
| FDA fees | 100 | 2,402 | (2,302) | (96)% |
| Testing, operating and lab supplies | 7,762 | 4,428 | 3,334 | 75% |
| Depreciation | 2,185 | 2,397 | (212) | (9)% |
| Other expenses | 1,703 | 2,020 | (317) | (16)% |
| Total research and development expenses | $21,982 | $19,199 | $2,783 | 14% |

Research and development costs consist primarily of costs associated with the research and development of our product candidates, such as salaries and other personnel related expenses for employees involved with research and development activities, manufacturing pre-launch inventory, clinical trials, FDA fees, testing, operating and lab supplies, depreciation and other related expenses. We expense research and development costs as incurred.

Pre-launch inventory expense increased due to purchases related to Primatene® Mist. Testing, operating and lab supplies increased due to expenditures on materials for our pipeline products, particularly production of APIs for our pipeline at our ANP facility. Clinical trials expense increased due to external studies related to our generic product pipeline. This increase was partially offset by a decrease in FDA fees pertaining to the NDA filing of our intranasal naloxone product candidate that was submitted in the second quarter of 2016.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. These costs will fluctuate significantly from quarter to quarter based on the timing of various clinical trials, the pre-launch costs associated with new products, and FDA filing fees. As we undertake new and challenging research and development projects, we anticipate that the associated annual costs will increase significantly over the next several quarters and years.

### Gain on sale of intangible assets

*(in thousands)*

|  | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | --- |
| Gain on sale of intangible assets | $(2,643) | $— | $(2,643) | N/A |

In February 2017, we sold the ANDAs that we acquired in March 2016 and recognized a gain of $2.6 million (see Note 3 and Note 9 to the condensed consolidated financial statements for more information).

### Provision for income tax expense

*(in thousands)*

|  | Six Months Ended June 30, 2017 | 2016 | Change Dollars% |  |
| --- | ---: | ---: | ---: | --- |
| Income tax benefit | $1,812 | $4,184 | $(2,372) | NM |
| Effective tax rate | 39% | 31% |  |  |

The difference in income tax expense was primarily due to the change in pre-tax income positions.

### Liquidity and Capital Resources

### Cash Requirements and Sources

We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development‑stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand and improve our manufacturing facilities in the United States, China and France. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report on Form 10-Q. As of June 30, 2017, our foreign subsidiaries collectively held $16.4 million in cash and cash equivalents. We do not plan to repatriate foreign earnings to the United States. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent company’s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.

We maintain a shelf registration statement on Form S-3 pursuant to which we may, from time to time, sell up to an aggregate of $250 million of our common stock, preferred stock, depositary shares, warrants, units, or debt securities. If we require or elect to seek additional capital through debt or equity financing in the future, we may not be able to raise capital on terms acceptable to us or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.

Working capital increased by $6.4 million to $129.9 million at June 30, 2017, compared to $123.5 million at December 31, 2016.

### Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the six months ended June 30, 2017:

*(in thousands)*

| Statement of Cash Flow Data: Net cash provided by (used in) | Six Months Ended June 30, 2017 |
| --- | ---: |
| Operating activities | $26,972 |
| Investing activities | (15,656) |
| Financing activities | (1,403) |
| Effect of exchange rate changes on cash | 277 |
| Net increase in cash and cash equivalents | $10,190 |

#### Sources and Use of Cash

#### Operating Activities

Net cash provided by operating activities was $27.0 million for the six months ended June 30, 2017, which included net income of $2.9 million. Non-cash items were comprised of $7.7 million of depreciation and amortization, $8.7 million of share-based compensation expense, and a gain of $2.6 million on the sale of long-lived assets.

Over the six months ended June 30, 2017, accounts receivable declined by approximately $2.8 million primarily due to the timing of customer purchases and payments. Inventories decreased by approximately $7.0 million primarily due to the timing of component and raw material purchases and sales deliveries as well as a non-cash charge of $5.1 million to adjust certain inventory items to their net realizable value. Accounts payable and accrued liabilities increased by approximately $4.3 million primarily due to the timing of payments which will lead to cash outflows in the third quarter.

#### Investing Activities

Net cash used in investing activities was $15.7 million for the six months ended June 30, 2017, primarily as a result of $13.6 million in purchases of property, machinery, and equipment, including the associated capitalized labor and interest on self-constructed assets. Restricted short-term investment increased by $2.8 million. Additionally, $1.1 million in deposits were made for machinery and equipment during the first half of 2017. This was partially offset by the receipt of the $2.0 million initial payment relating to the sale of the various ANDAs in February 2017 (see Note 9 to the condensed consolidated financial statements for more information).

#### Financing Activities

Net cash used in financing activities was $1.4 million for the six months ended June 30, 2017, primarily as a result of $19.7 million relating to the repurchase of our common stock, which was offset by $9.8 million of proceeds received from stock options exercised related to our equity plans and purchases of our common stock through the ESPP. Additionally, we received proceeds of $11.1 million from borrowings on a mortgage loan and an equipment line of credit, and made $2.6 million in principal payments on our long-term debts.

### Indebtedness

For more information regarding our outstanding indebtedness, see “Part I – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Debt”.

### Contractual Obligations

There have been no material changes outside the ordinary course of our business in the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, except that our outstanding debt obligations have changed as follows:

*(in thousands)*

|  | June 30, 2017 | December 31, 2016 | Change |
| --- | ---: | ---: | ---: |
| Short-term debt and current portion of long-term debt | $6,205 | $5,366 | $839 |
| Long-term debt | 40,107 | 32,356 | 7,751 |
| Total debt | $46,312 | $37,722 | $8,590 |

As of June 30, 2017, we had $43.0 million in unused borrowing capacity under revolving lines of credit with Cathay Bank and East West Bank.

### Collaboration Agreement with a Medical Device Manufacturer

In 2014, we entered into a collaboration agreement with a medical device manufacturer to develop a drug delivery system to be used by us for one of our pipeline products. As of June 30, 2017, we have paid an upfront payment of $0.5 million and have paid $1.5 million in milestone payments under this agreement, which were classified as research and development expense as the milestones were met. We are obligated to pay up to an additional $0.5 million if certain milestones are met. As of June 30, 2017, no such obligation existed. Pursuant to the collaboration agreement, if the medical device manufacturer is successful in the development of this drug delivery system and our pipeline products receive appropriate regulatory approval, we intend to enter into a commercial supply agreement with such medical device manufacturer for a minimum purchase of 1.0 million units during the first 12 months.

### Critical accounting policies

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2016. There were no material changes to our critical accounting policies during the six months ended June 30, 2017.

### Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, refer to Note 2 in the accompanying “Notes to Condensed Consolidated Financial Statements” in this Quarterly Report.

### Off-Balance Sheet Arrangements

We do not have any relationships or financial partnerships with unconsolidated entities, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

### Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.

From November 29, 2016 through December 7, 2016, our IMS facility in South El Monte, California was subject to an inspection by the FDA. The inspection included a review of our compliance with cGMP regulations and verification of corrective actions implemented from a previous inspection in July 2015. The inspection resulted in multiple observations on Form 483, an FDA form on which deficiencies are noted after an FDA inspection. We responded to those observations on December 29, 2016, within the required 15-working day window of the issuance of the Form 483. A follow up letter to the FDA District Office was additionally sent on January 31, 2017, outlining additional progress on our corrective action plan submitted in December. We believe that our responses to Form 483 will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From January 30, 2017 through February 09, 2017, our IMS facility in South El Monte, California was subject to a preapproval inspection by the FDA. The inspection included a review of our corrective actions taken from the recent cGMP inspection as well as review of data to support our pending application. The inspections resulted in multiple observations on Form 483. We responded to those observations on February 14, 2017. We believe that our responses to Form 483 will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From March 13, 2017 through March 31, 2017, our Amphastar facility in Rancho Cucamonga, California was subject to a preapproval inspection by the FDA. The inspection included a review of our corrective actions taken from the previous cGMP inspection in July 2014 as well as review of data to support our pending applications. The inspections resulted in multiple observations on Form 483. We fully responded to those observations on April 22, 2017. We believe that our responses to Form 483 will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From April 24, 2017 through April 28, 2017, our facility in Nanjing, China was subject to an inspection by the FDA. The purpose was a pre-approval inspection for the manufacture of API. The inspection resulted in several observations on Form 483. We responded to those observations on May 19, 2017, and believe that our responses to Form 483 will satisfy the requirements of the FDA and that no significant further actions will be necessary.

## Market risk

As filed, 4,708 characters.

The following discussion provides forward-looking quantitative and qualitative information about our potential exposure to market risk. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

#### Investment Risk

We regularly review the carrying value of our investments and identify and recognize losses, for income statement purposes when events and circumstances indicate that any declines in the fair values of such investments below our accounting basis are other than temporary. As of June 30, 2017, we did not have any such investments.

As of June 30, 2017, we had $12.3 million deposited in five banks located in China, $3.9 million deposited in one bank located in France, and $0.2 million deposited in one bank located in the United Kingdom. We also maintained $52.7 million in cash equivalents that include money market accounts, money market funds, MMIDAS, and ICS accounts as of June 30, 2017. The remaining amounts of our cash equivalent as of June 30, 2017, are in non-interest bearing accounts.

The MMIDAS accounts and ICS accounts allow us to distribute our funds among a network of depository institutions that are re‑allocated such that each deposit account is below the $250.0 thousand Federal Deposit Insurance Corporation, or FDIC, limit, thus providing greater FDIC insurance coverage for our overall cash balances. We have not experienced any losses in such accounts, nor do we believe we are exposed to any significant credit risk on our bank account balances.

#### Interest Rate Risk

Our primary exposure to market risk is interest‑rate‑sensitive investments and credit facilities, which are affected by changes in the general level of U.S. interest rates. Due to the nature of our short-term investments, we believe that we are not subject to any material interest rate risk with respect to our short-term investments.

As of June 30, 2017, we had $46.3 million in long-term debts and capital leases outstanding. Of this amount, $16.1 million had variable interest rates which were not locked-in through fixed interest rate swap contracts. The debt with variable interest rate exposure had a weighted-average interest rate of 4.0% at June 30, 2017. An increase in the index underlying these rates of 1% (100 basis points) would increase our annual interest expense on the debts with variable interest rate exposure by approximately $0.2 million per year.

#### Foreign Currency Exchange Risk

Our products are primarily sold in the U.S. domestic market, and for the three and six months ended June 30, 2017 and 2016, foreign sales were minimal. Therefore, we have little exposure to foreign currency price fluctuations. However, as a result of our acquisition of the API manufacturing business in Éragny-sur-Epte, France, we are exposed to market risk related to changes in foreign currency exchange rates. Specifically, our insulin sales contracts are primarily denominated in Euros, which are subject to fluctuations relative to the USD. We do not currently hedge our foreign currency exchange rate risk. At this time, an immediate 10% change in currency exchange rates would not have a material effect on our financial position, results of operations or cash flows.

Our Chinese subsidiary, ANP, maintains their books of record in Chinese Yuan. These books are remeasured into the functional currency of USD, using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in our statement of operations.

Our French subsidiary, AFP, maintains their books of record in Euros. Our U.K. subsidiary, IMS UK, maintain its books of record in Great Britain Pounds. These books are translated to USD at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss). We do not undertake hedging transactions to cover our foreign currency exposure.

As of June 30, 2017, we had cash balances denominated in foreign currencies in the amount of $4.2 million.

## Controls and procedures

As filed, 3,215 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

### Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## Risk factors

As filed, 4,286 characters.

Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 15, 2017.

***Some of our products are marketed without FDA approval and may be subject to enforcement actions by the FDA.***

A number of our prescription products are marketed without FDA approval. These products, like many other prescription drugs on the market that FDA has not formally evaluated as being effective, contain active ingredients that were first marketed prior to the enactment of the Federal Food, Drug, and Cosmetic Act, or FFDCA. The FDA has assessed these products in a program known as the “Prescription Drug Wrap-Up” and has stated that these drugs cannot be lawfully marketed unless they comply with certain “grandfather” exceptions to the definition of “new drug” in the FFDCA. These exceptions have been strictly construed by FDA and by the courts, and the FDA has stated that it is unlikely that any of the unapproved prescription drugs on the market, including certain of our drugs, qualify for the exceptions. At any time, the FDA may require that some or all of our unapproved prescription drugs be submitted for approval and may direct that we recall these products and/or cease marketing the products until they are approved. The FDA may also take enforcement actions based on our marketing of these unapproved products, including but not limited to the issuance of an untitled letter or a warning letter, and a judicial action seeking injunction, product seizure and civil or criminal penalties. The enforcement posture could change at any time and our ability to market such drugs could terminate with little or no notice. Moreover, if our competitors seek and obtain approval and market FDA-approved prescription products that compete against our unapproved prescription products, we would be subject to a higher likelihood that FDA may seek to take action against our unapproved products. Such competitors have brought and may bring claims against us alleging unfair competition or related claims.

As a result of our meetings with the FDA in 2009, we decided to discontinue all of our products that were subject to the Prescription Drug Wrap-Up program, with the exception of epinephrine in vial form. These products were all produced at our subsidiary, IMS. During the third quarter of 2010, the FDA requested that we reintroduce several of the withdrawn products to cope with a drug shortage, while we prepared and filed applications for approval of the products. Between August and October, 2010, we reintroduced atropine, calcium chloride, morphine, dextrose, epinephrine prefilled syringes, epinephrine injection, USP vial, and sodium bicarbonate injections, and continue to market these products without FDA approval. For the years ended December 31, 2016, 2015, and 2014, we recorded net revenues of $52.1 million, $40.2 million, and $27.0 million, respectively, from unapproved products. For the six months ended June 30, 2017 and 2016, we recorded net revenues of $37.2 million, $22.5 million, respectively. The FDA recently requested us to discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which has been marketed under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. We discontinued selling this product in the second quarter of 2017. For the six months ended June 30, 2017 and for the year ended December 31, 2016, we recognized $17.9 million and $18.6 million, in net revenues for the sale of this product, respectively. The charge of $3.3 million was included in the cost of revenues in our consolidated statements of operations for the year ended December 31, 2016, to adjust the related inventory items and firm purchase commitments to their net realizable value due to the anticipated discontinuation of the product. We have filed four ANDAs and are preparing additional applications with respect to other products in order to finally mitigate all risk associated with the marketing of unapproved drug products. In the interim, we continue to operate within the FDA Compliance Policy Guide, CPG Sec. 440.100 Marketed New Drugs Without Approved NDAs and ANDAs.

Filed Aug 9, 2017.
Source: SEC EDGAR, the filing index for accession 0001297184-17-000028. Last ingested by Listed: Nov 6, 2026, 17:01 ET. No prices; not investment advice.
